Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

14.77
-0.8300-5.32%
Post-market: 15.060.2900+1.96%19:25 EDT
Volume:1.36M
Turnover:20.35M
Market Cap:920.05M
PE:-4.27
High:15.83
Open:15.55
Low:14.58
Close:15.60
52wk High:71.50
52wk Low:7.76
Shares:62.29M
Float Shares:40.64M
Volume Ratio:0.52
T/O Rate:3.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4602
EPS(LYR):-3.4602
ROE:-207.10%
ROA:-16.21%
PB:4.63
PE(LYR):-4.27

Loading ...

uniQure Reports Sustained Enzyme Increases in Phase I/IIa Fabry Disease Gene Therapy Trial

Reuters
·
Feb 06

A Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations

Simply Wall St.
·
Feb 04

uniQure Initiated at Equal-Weight by Barclays

Dow Jones
·
Jan 28

Barclays Initiates Coverage on uniQure N.V With Equal Weight Rating, $31 Price Target

MT Newswires Live
·
Jan 28

uniQure initiated with an Equal Weight at Barclays

TIPRANKS
·
Jan 28

uniQure NV Director Robert Gut Reports Disposal of Common Shares

Reuters
·
Jan 15

uniQure Showcases Gene Therapy Leadership and Pipeline Progress in New Corporate Presentation

Reuters
·
Jan 13

uniQure NV Director Jack Kaye Reports Disposal of Common Shares

Reuters
·
Jan 13

uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway

Benzinga
·
Jan 10

US-Listed Shares of Uniqure Rise 13% Premarket as FDA Review Talks Revive Hopes for Huntington's Therapy

THOMSON REUTERS
·
Jan 09

BUZZ-UniQure rises as US FDA review talks revive hopes for Huntington's therapy

Reuters
·
Jan 09

uniQure announces Type A meeting scheduled with FDA

TIPRANKS
·
Jan 09

Does uniQure (QURE) FDA Feedback on AMT-130 Reframe Its Risk, Funding and Strategy Profile?

Simply Wall St.
·
Dec 18, 2025

uniQure call volume above normal and directionally bullish

TIPRANKS
·
Dec 17, 2025

What's Going On With uniQure Stock On Tuesday?

Benzinga
·
Dec 17, 2025

uniQure Is Maintained at Buy by Chardan Capital

Dow Jones
·
Dec 05, 2025

Why uniQure Stock Is Trading Lower After FDA Meeting Update

Benzinga_recent_news
·
Dec 05, 2025

UniQure Shares Drop After More Negative News From FDA on Huntington's Disease Drug

Dow Jones
·
Dec 04, 2025

uniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission

MT Newswires Live
·
Dec 04, 2025

uniQure put volume heavy and directionally bearish

TIPRANKS
·
Nov 27, 2025